S&P 500
7,679.80
+0.22%
Dow Jones
53,584.30
+0.23%
Nasdaq 100
29,229.20
+0.56%
Russell 2000
3,009.10
+0.30%
FTSE 100
10,910.50
+0.44%
Nikkei 225
66,037.70
+1.04%
Ashland

Ashland (ASH) Q3 2026 Earnings

Reported Jul 28, 2026 at 5:10 PM ET · SEC Source

Q3 26 EPS

$1.02

BEAT +3.62%

Est. $0.98

Q3 26 Revenue

$497.0M

BEAT +2.27%

Est. $486.0M

vs S&P Since Q3 26

+6.1%

BEATING MARKET

ASH +11.1% vs S&P +5.0%

Market Reaction

Did ASH Beat Earnings? Q3 2026 Results

Ashland Inc. Delivered a clean beat across both top and bottom lines in fiscal Q3 2026, posting adjusted diluted EPS of $1.02 against a consensus estimate of $0.98 and revenue of $497.00 million that topped expectations by 2.27% while climbing 7.3% y… Read more Ashland Inc. Delivered a clean beat across both top and bottom lines in fiscal Q3 2026, posting adjusted diluted EPS of $1.02 against a consensus estimate of $0.98 and revenue of $497.00 million that topped expectations by 2.27% while climbing 7.3% year over year. The standout driver was broad volume momentum, with a six percent increase across all four business segments fueling the sales advance; Life Sciences led the way with 11 percent growth to $180.00 million and a 33% Adjusted EBITDA margin, while Intermediates rose 12 percent on strengthening NMP demand from electric vehicle battery customers. Consolidated Adjusted EBITDA reached $109.00 million at a 21.9% margin, though the figure dipped four percent year over year as lingering effects from earlier production challenges and inflationary cost pressures weighed on conversion. The results arrive as activist investors press for a strategic review of the company, adding backdrop to management's reaffirmed full-year sales guidance of $1.83 billion to $1.87 billion and Adjusted EBITDA of $385.00 million to $400.00 million, with sequential profitability improvement expected in Q4.

Key Takeaways

  • • Broad-based volume growth of six percent across all business units
  • • Pricing actions recovering higher raw material costs, approximately one percent pricing increase
  • • Strong commercial execution and share gains in coatings and performance specialties
  • • Globalize and innovate strategies exceeding targets across differentiated portfolio
  • • Disciplined inventory management supporting cash generation
  • • Favorable foreign currency movements contributing $3 million to sales

ASH Forward Guidance & Outlook

Ashland reaffirmed full-year fiscal 2026 sales guidance of $1,835 to $1,870 million and Adjusted EBITDA guidance of $385 to $400 million. The company revised its adjusted EPS outlook to low-to-mid-single digit growth (from mid-to-high-single digit growth), reflecting a higher tax rate from unfavorable discrete items. Ongoing Free Cash Flow conversion is expected to be greater than 50% of Adjusted EBITDA with capital expenditures of approximately $90 million. Management expects continued sequential improvement in Q4 as operational performance improves and pricing actions achieve greater realization. Core Life Sciences and Personal Care markets demonstrate resilient demand. Raw material and freight costs are expected to remain elevated amid geopolitical supply pressures, though pricing actions are expected to offset these impacts over time. The company expects to carry improving earnings momentum into fiscal 2027.

24/7 Wall St

ASH YoY Financials

Q3 2026 vs Q3 2025, source: SEC Filings

24/7 Wall St

ASH Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q3 26

“Ashland's third-quarter results reflected broad-based demand and strong commercial execution across the portfolio. Sales increased seven percent year-over-year, with growth achieved across all business units and regions. Our teams continued to successfully recover higher raw material costs through pricing actions, preserving margins while maintaining strong customer relationships.”

— Guillermo Novo, Q3 2026 Earnings Press Release

Back to ASH Stock Page